Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS2 | Q96GW9 | 7/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 6/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.33 |
| ▸ | CDK2 | P24941 | 6/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | CDK4 | P11802 | 4/20 | 0.31 |
| ▸ | CCND1 | P24385 | 4/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.31 |
| ▸ | CDK1 | P06493 | 3/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20596003 | 0.86 | MARS2 (0.71) | MARS2CCNE2CCNE1CDK2P2RX7 | |
| SCHEMBL23419627 | 0.83 | MARS2 (0.74) | MARS2 | |
| SCHEMBL23419282 | 0.82 | MARS2 (0.76) | MARS2P2RX7 | |
| SCHEMBL23419474 | 0.77 | MARS2 (0.65) | MARS2ADORA2B | |
| SCHEMBL23419308 | 0.76 | MARS2 (0.65) | MARS2ADORA2B | |
| SCHEMBL23419297 | 0.76 | MARS2 (0.65) | MARS2P2RX7 | |
| SCHEMBL23419718 | 0.74 | MARS2 (0.77) | MARS2P2RX7 | |
| SCHEMBL23419769 | 0.73 | MARS2 (0.59) | MARS2 | |
| SCHEMBL23391426 | 0.73 | MARS2 (0.49) | MARS2 | |
| SCHEMBL23391450 | 0.73 | MARS2 (0.59) | MARS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | MARS2 12/4885CCNE2 4579/4885CCNE1 3709/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | MARS2 5/4885CCNE2 4464/4885CCNE1 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.